Syndax’s Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision

2025 年 10 月 4 日 business, finance, healthcare, medicine, pharmaceuticals

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the best stocks to buy under $20. On September 19, Syndax Pharmaceuticals announced a major milestone: the National Comprehensive Cancer Network/NCCN updated its Clinical Practice Guidelines in Oncology/NCCN Guidelines for Acute Myeloid Leukemia/AML to include Revuforj (revumenib). Revumenib received a Category 2A recommendation for the treatment of relapsed […]

Dow, S&P 500 manage record closing highs; Nasdaq falls in volatile session

2025 年 10 月 3 日 business, economy, finance, politics, technology

The S&P 500 and Dow achieved record closing highs Friday, navigating a volatile session amid an ongoing government shutdown. Interest rate-cut expectations strengthened, driven by weak economic data, including contracting services employment. Traders now anticipate a Fed rate cut in October as almost certain, with another probable in December, despite concerns about a prolonged shutdown’s impact.